Exploring Analyst Estimates for HealthEquity (HQY) Q3 Earnings, Beyond Revenue and EPS

Analysts on Wall Street project that HealthEquity (HQY) will announce quarterly earnings of $0.90 per share in its forthcoming report, representing an increase of 15.4% year over year. Revenues are projected to reach $319.96 million, increasing 6.5% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.Bearing this in mind, let's now explore the average estimates of specific HealthEquity metrics that are commonly monitored and projected by Wall Street analysts.Based on the collective assessment of analysts, 'Revenue- Service' should arrive at $119.50 million. The estimate indicates a year-over-year change of +0.3%.Analysts expect 'Revenue- Custodial' to come in at $156.61 million. The estimate points to a change of +11.1% from the year-ago quarter.Analysts predict that the 'Revenue- Interchange' will reach $42.88 million. The estimate suggests a change of +6.4% year over year.The collective assessment of analysts points to an estimated 'Total HSA Assets' of $33.68 billion. The estimate is in contrast to the year-ago figure of $29.99 billion.The consensus estimate for 'Total HSA investments' stands at $16.22 billion. Compared to the present estimate, the company reported $13.60 billion in the same quarter last year.Analysts forecast 'CDBs Accounts' to reach 7.05 million. Compared to the current estimate, the company reported 6.96 million in the same quarter of the previous year.Analysts' assessment points toward 'Total Accounts' reaching 17.26 million. Compared to the present estimate, the company reported 16.46 million in the same quarter last year.The average prediction of analysts places 'Total HSA cash' at $17.43 billion. The estimate compares to the year-ago value of $16.39 billion.The combined assessment of analysts suggests that 'HSAs Accounts' will likely reach 10.21 million. The estimate compares to the year-ago value of 9.51 million. View all Key Company Metrics for HealthEquity here>>> Over the past month, HealthEquity shares have recorded returns of +11.2% versus the Zacks S&P 500 composite's +0.4% change. Based on its Zacks Rank #3 (Hold), HQY will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report HealthEquity, Inc. (HQY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks